ClinicalTrials.gg
RecruitingNCT05984979VOCircleUpdated Dec 8, 2025

The Daytime Circadian Rhythm in Exhaled Volatile Organic Compounds in People Living Without and Diabetes

An observational study in Diabetes Mellitus, sponsored by University of Bern. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-08.

Sponsored by University of Bern · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Aug 2023; still recruiting 3 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Other
Enrollment
60
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 87 studies in Diabetes Mellitus with a site in Switzerland — 9 open to participants now, 11 under way, none of them phase 3. Diabetes Mellitus · Switzerland.

Planned enrollment
18th of 24
60 · median 600
Started
2023
with 6 others
Observational
24 of 87
5 open now
Primary completion
2026-06
later than 2 of 10 live
Registered
80th of 87
by date
Lead sponsor
3 of 87
University of Bern

Among the 87 studies in Diabetes Mellitus with a site in Switzerland, this one is the 18th largest by planned enrollment of the 24 observational ones that give a count, is one of 7 that started in 2023, is one of 24 observational ones, reaches primary completion later than 2 of the 10 other live ones, and was the 80th registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

9 of the 87 studies in Diabetes Mellitus with a site in Switzerland are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies in Diabetes Mellitus with a site in Switzerland, or all of them as a file.
02

Study summary

Exhaled volatile organic compounds will be measured during daytime with the goal to identifying circadian variability. The study incudes three subgroups: people without diabetes, people with type 1 diabetes, and people with type 2 diabetes. A total of 60 people will be recruited for the study.

03

Conditions studied

  • Diabetes Mellitus

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

60 participants with the following subgroups: Subgroup 1: People without diabetes Subgroup 2: People diagnosed with T1D Subgroup 3: People diagnosed with T2D

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subgroup 1:

  • Age 18 or older
  • below 6.5%
  • Written

Subgroup 2:

  • Age 18 or older
  • T1D (Type 1 diabetes) with MDI (multiple daily injection) or CSII (Continuous subcutaneous insulin infusion therapy) therapy >1 year
  • Written informed consent

Subgroup 3

  • Age 18 or older
  • T2D (Type 2 diabetes) with oral antidiabetic medication or insulin therapy
  • Written informed consent

Exclusion criteria

Exclusion criteria

  • Pregnancy or breastfeeding
  • Smoking (last cigarette less than 6 months ago)
  • Any chronical lung and intestinal disease diagnosis (such as intestinal bowel disease (IBD); asthma; (chronic obstructive pulmonary disease); lung cancer, …)
  • Coeliac disease
  • Lactose and fructose intolerance
  • Any acute disease diagnosis (such as viral or bacterial infection)
  • Drinking habit of more than four units of alcohol per day
  • Current inhaled medicines treatments
  • Antibiotic treatment in the previous 4 months
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Observational model
Other
Time perspective
Other
Enrollment
60 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • People without diabetes

    Other: Standardized meal

  • People with type 1 diabetes

    Other: Standardized meal

  • People with type 2 diabetes

    Other: Standardized meal

Interventions

  • OtherStandardized meal

    The participants will receive a standardized meal for breakfast

06

What researchers measure

Primary outcomes

  1. VOC Patterns over time as gallery plots

    Gallery plots (3D visualization of retention index, drift time, ion current) from selected VOC peaks over time.

    Time frame: During the study procedure (approximately 8 hours)

  2. VOC Patterns over time as boxplots

    Box plots from selected VOC peaks over time.

    Time frame: During the study procedure (approximately 8 hours)

Secondary outcomes

  1. Capillary blood glucose

    Correlation between capillary blood glucose and VOCs

    Time frame: During the study procedure (approximately 8 hours)

  2. Correlation between VOCs in breath intestinal microbiota

    Correlation between VOCs in breath and intestinal microbiota species abundance

    Time frame: day 1

  3. Correlation between VOCs in breath oral microbiota

    Correlation between VOCs in breath and oral microbiota species abundance

    Time frame: day 1

  4. Correlation between VOCs and subgroups

    Wilcoxon signed-rank test will be used to explore if the patterns in VOCs differ between subgroup: people without diabetes, people living with T1D, and people living with T2D

    Time frame: day 1 or 8 hours

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Nicolier C, Rothenbuhler M, Balmer ML, Witthauer L. Daytime circadian patterns of exhaled volatile organic compounds in adults without and with type 1 and type 2 diabetes: protocol for an exploratory observational study. BMJ Open. 2026 Apr 8;16(4):e113892. doi: 10.1136/bmjopen-2025-113892. PubMed 41951262 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Jun 2026, 34 months after the start.

Of 534 non-industry observational studies under Diabetes Mellitus, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 159. This study's planned 34 months is below that.

Counting every sponsor, half of 643 studies reached it within 36 months; a quarter within 14 and three quarters within 122.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2023
First posted
Aug 9, 2023
StartActual
Aug 7, 2023
Primary completionEst.
Jun 30, 2026
CompletionEst.
Jun 30, 2026
Last update
Dec 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05984979
Lead sponsor
University of Bern
Collaborators
Insel Gruppe AG, University Hospital Bern, DCB Research AG
Responsible party
Sponsor
First posted
Aug 9, 2023
Start date
Aug 7, 2023
Primary completion
Jun 30, 2026 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
Dec 8, 2025

Study contacts

Lilian Witthauer
Contact
lilian.witthauer@unibe.ch
+41 31 664 22 77
Lilian Witthauer, Prof.Dr.
principal investigator · University of Bern

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion